A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

In a significant medical breakthrough, researchers from King’s College London have found that semaglutide, a drug commonly ...

Financing follows completion of enrollment of Phase 3 NATiV3 study evaluating lanifibranor in MASH and satisfaction of other ...

An international study led by the director of Virginia Commonwealth University’s liver institute suggests that the substance in Ozempic and Wegovy can halt and even reverse a ...

The report emphasized the progress of pegozafermin through Phase 3 clinical development, with positive results from Phase ...

Zurich (Switzerland), May 5, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today ...